Anti-inflammatoryand anticoagulant properties of the protein C system in inflammatory bowel disease

Polskie Archiwum Medycyny Wewnetrznej

Volumn 122, Issue 5, 2012, Pages 209-216

  Owczarek, Danuta ^a   Cibor, Dorota ^a   Sałapa, Kinga ^a   Cieśla, Andrzej ^a   Głowacki, Mikołaj K ^a   Pocztar, Halina ^a   Mach, Tomasz H ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Inflammation; Inflammatory bowel disease; Protein C; Thrombomodulin; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; INTERLEUKIN 6; MACROGOL; PROTEIN C; PROTEIN S; RECOMBINANT PROTEIN; THROMBOMODULIN; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

ADULT; AGED; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DISEASE MARKER; ENTERITIS; FEMALE; HEMOSTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; ULCERATIVE COLITIS; BLOOD; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; BIOLOGICAL MARKERS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-6; MALE; MIDDLE AGED; PROTEIN C; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84863445883     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Tsiolakidou G, Koutroubakis IE. Trombosis and inflammatory bowel disease - the role of genetic risk factors. World J Gastroenterol. 2008; 14: 4440-4444.
2. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005; 131: 417-430. (Pubitemid 43899639)
3. Van de Wouwer M, Collen D, Conway EM. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol. 2004; 24: 1374-1383. (Pubitemid 39050428)
4. Fisher CJ Jr, Yan SB. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med. 2000; 28 (9 Suppl): S49-S56.
5. Rivard GE, David M, Farrell C, Schwarz HP. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr. 1995; 126: 646-652.
6. White B, Livingstone W, Murphy C, et al. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood. 2000; 96: 3719-3724.
7. Kim AY, Walinsky PL, Kolodgie FD, et al. Early loss of thrombomodulin expression impairs vein graft thromboresistance: implications for vein graft failure. Circ Res. 2002; 90: 205-212. (Pubitemid 34627090)
8. Waugh JM, Yuksel E, Li J, et al. Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model. Circ Res. 1999; 84: 84-92. (Pubitemid 29074883)
9. Weber P, Husemann S, Vielhaber H, et al. Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1999; 28: 418-422. (Pubitemid 30349252)
10. Remková A, Kovácová E, Príkazská M, Kratochvíl'ová H. Thrombomodulin as a marker of endothelium damage in some clinical conditions. Eur J Intern Med. 2000; 11: 79-84. (Pubitemid 30169182)
11. Boehme MW, Autschbach F, Zuna I, et al. Elevated serum levels and reduces immunohistochemical expression of thrombomodulin in active ulcerative colitis. Gastroenterology. 1997; 113: 107-117. (Pubitemid 27281764)
12. Stenson WF. Inflammatory bowel diseases. In: Yamada T, ed. Texbook of Gastroenterology. Vol. 2. 2nd ed. Philadelphia, PA: JB Lippincott; 1995: 1761-1772.
13. Owczarek D, Undas A, Foley JH, et al. Activated thrombin activatable inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases. J Crohns Colitis. 2012; 6: 13-20.
14. Rentsch M, Beham A, Schlitt HJ, Jauch KW. Crohn's disease activity index and Vienna classification - is it worthwhile to calculate before surgery? Dig Surg. 2006; 23: 241-249.
15. van Deventer SJ, Tami JA, Wedel MK. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut. 2004; 53: 1646-1651.
16. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55: 749-753. (Pubitemid 43764536)
17. Owczarek D, Cibor D, Mach T. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), arginine, and 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha) level in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2010; 16: 52-57.
18. Malm L, Laurell M, Dahlbäck B. Changes in the plasma levels of vitamin-K dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol. 1988; 68: 437-443.
19. Van Bodegraven AA. Haemostasis in inflammatory bowel disease: clinical relevance. Scand J Gastroenterol Suppl. 2003; 239: 51-62. (Pubitemid 38112916)
20. Stouthard JM, Levi M, Hack CE, et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost. 1996; 76: 738-742. (Pubitemid 26388179)
21. Van de Wouwer M, Collen D, Conway EM. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol. 2004; 24: 1374-1383. (Pubitemid 39050428)
22. Sawyerr AM, Smith MS, Hall A, et al. Serum concentration of von Willebrand factor and soluble thrombomodulin indicate alteration of endothelial function in inflammatory bowel diseases. Dig Dis Sci. 1995; 40: 793-799.
23. Souto JC, Martínez E, Roca M, et al. Protrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci. 1995; 40: 1883-1889.
24. Faioni EM, Ferrero S, Fontana G, et al. Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease. Crit Care Med. 2004; 32 (5 Suppl): S266-S227.
25. Scaldaferri F, Sans M, Vetrano S, et al. Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. J Ciln Invest. 2007; 117: 1951-1960. (Pubitemid 47036329)
26. Boehme MW, Deng Y, Raeth U, et al. Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies. Immunology. 1996; 87: 134-140. (Pubitemid 26027567)
27. Owczarek D, Cibor D, Szczepanek M, Mach T. Biological therapy of inflammatory bowel disease. Pol Arch Med Wewn. 2009; 119: 84-88.
28. Aleksic N, Wang YW, Ahn C, et al. Assessment of coronary heart disease risk by combined analysis of coagulation factors. Atherosclerosis. 2008; 198: 294-300.
29. Hosaka Y, Higuchi T, Tsumagari M, Ishii H. Inhibition of invasion and experimental metastasis of murine melanoma cells by human soluble thrombomodulin. Cancer Lett. 2000; 161: 231-240.
30. Van de Wouwer M, Plaisance S, De Vriese A, et al. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost. 2006; 4: 1813-1824. (Pubitemid 44144810)
31. Ikeguchi H, Maruyama S, Morita Y, et al. Effects of human soluble thrombomodulin on experimental glomerulonephritis. Kidney Int. 2002; 61: 490-501. (Pubitemid 34102589)
32. Griffin JH, Fernández JA, Gale AJ, Mosnier LO. Activated protein C. J Thromb Haemost. 2007; 5 (Suppl 1): 73-80. (Pubitemid 46958820)
33. Saibeni S, Vecchi M, Valsecchi C, et al. Reduced free protein S levels in patients with inflammatory bowel disease: prevalence, clinical relevance, and role of anti-protein S antibodies. Dig Dis Sci. 2001: 46: 637-643. (Pubitemid 32299822)
34. Koutroubakis IE, Sfiridaki A, Mouzas IA, et al. Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. Am J Gastroenterol. 2000; 95: 190-194. (Pubitemid 30041557)
35. Kume K, Yamasaki M, Tashiro M, et al. Activations of coagulation and fibrinolysis secondary to bowel inflammation in patients with ulcerative colitis. Inter Med. 2007; 46: 1323-1329.
36. Aadland E, Odegaard OR, Røseth A, Try K. Free protein S deficiency in patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1992; 27: 957-960.
37. Saibeni S, Saladino V, Chantarangkul V, et al. Increased thrombin generation in inflammatory bowel diseases. Thromb Res. 2010; 125: 278-282.
38. Esmon CT. Is APC activation of endothelial cell PAR1 important in severe sepsis?: No. J Thromb Haemost. 2005; 3: 1910-1911.
39. van Bodegraven AA, Schoorl M, Linskens RK, et al. Persistant activation of coagulation and fibrynolysis after treatment of active ulcerative colitis. Eur J Gastroenterol Hepatol 2002; 14: 413-418.
40. Srirajaskanthan R, Winter M, Muller AF. Venous thrombosis in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2005; 17: 697-700. (Pubitemid 40896413)
41. Faioni EM, Valsecchi C, Palla A, et al. Free protein S deficiency is a risk factor for venous thrombosis. Thromb Haemost. 1997; 78: 1343-1346. (Pubitemid 27491307)
42. Han KH, Hong KH, Park JH, et al. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation. 2004; 109: 2566-2571. (Pubitemid 38720558)
43. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension. 2004; 44: 6-11. (Pubitemid 38823477)
44. Danese S, Papa A, Saibeni S, et al. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol. 2007; 102: 174-186. (Pubitemid 46072059)